Summary of Key Points Core Viewpoint - The Anqing Market Supervision Administration conducted a food safety inspection of 101 samples across 11 categories, resulting in 98 compliant samples and 3 non-compliant samples, with local authorities taking action on the non-compliant products [2]. Group 1: Inspection Results - A total of 101 food samples were tested, covering categories such as pastries, grain products, meat products, edible oils, vegetable products, and frozen foods [2]. - Out of the 101 samples, 98 were found to be compliant with national food safety standards, while 3 samples were deemed non-compliant [2]. Group 2: Non-Compliant Products - The non-compliant products included: 1. Fried cooking oil from Qianshan Century Huacheng Hotel, with an acid value of 5.7 mg/g, exceeding the standard limit of 5 mg/g [2]. 2. Corn starch from Anqing Tianxian Vegetable and Fruit Supermarket, with mold and yeast counts of 1.7×10³ CFU/g, exceeding the limit of 10³ CFU/g [2]. 3. Tea crisp cakes from Anhui Huichang Food Co., with mold counts of 180 CFU/g, exceeding the limit of 150 CFU/g [2]. Group 3: Compliant Products - The compliant products included various health foods and beverages, such as: 1. Calcium gluconate oral solution from Jiangxi Yibainian Pharmaceutical Co., compliant with all standards [2]. 2. Calcium, iron, and zinc oral solution from Harbin Pharmaceutical Group, also compliant [2]. 3. Speakin® calcium chewable tablets from Xinshi Biotechnology Co., compliant with all standards [2].

Core Viewpoint - 哈药股份 is focusing on enhancing its product offerings and operational efficiency to drive growth and maintain competitiveness in the pharmaceutical industry Group 1: Business Operations and Strategy - The company held an analyst meeting on July 24, 2023, with participation from various financial institutions, discussing its business strategies and product lines [1] - The company plans to improve sales of its key nutritional supplements, with year-on-year sales growth of 72.84% for compound calcium gluconate oral solution and 51.30% for zinc gluconate oral solution [1] - The company is adjusting its marketing strategies for GNC China, focusing on e-commerce channel development, cost management, and brand value enhancement to ensure compliance and high-quality growth [1] Group 2: Research and Development - From 2024 to 2028, the company will focus its R&D efforts on five major therapeutic areas: cardiovascular, digestive metabolism, respiratory, anti-infection, and anti-tumor, along with elderly and pediatric medications [2] - The company aims to transition its R&D strategy from a focus on generic drugs to a combination of generics and innovative products, enhancing its product line [2] - The company has already received approval for a generic drug, lactulose oral solution, and is working on several other products expected to be approved in the near future [2] Group 3: Asset Management and Operational Improvement - The company is working on integrating raw material and formulation processes to control product costs and improve competitiveness [3] - The company is actively pursuing the revitalization of idle assets at its subsidiary, 哈药集团制药总厂, and has approved plans for phased asset disposal [3] Group 4: Long-term Vision and Mission - The company's long-term strategy is to provide quality medications for public health and to become a benchmark in the Chinese pharmaceutical industry [4] - The company aims for high-quality and sustainable development, supported by a complete product and talent pipeline, brand strategy, and marketing innovation [4]